Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 26 November 2025 - 3 December 2025

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples, these cross-currents are shaping how investors see BMY stock heading into 2026. BMY Stock Snapshot on 2 December 2025 On a day when the S&P 500 rose 0.25% and the Dow gained 0.39%, BMY underperformed peers: Johnson & Johnson ticked up slightly, while Pfizer and Abbott fell less than Bristol-Myers. MarketWatch For investors watching Google News and Discover, the headline
3 December 2025
··
Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life after its 2028 patent cliff. As of early afternoon on December 2, 2025, Merck shares trade around $101 (roughly $100.8–$101.0, down about 1% on the day), giving the company a market cap in the $250+ billion range. The stock sits not far below its recent 52‑week high of $105.84, after a powerful rally in November that lifted Merck more than
2 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026. Below is a news-style rundown of the latest price action, fundamentals, pipeline news, Wall Street forecasts and key risks that matter for Johnson & Johnson stock today. JNJ stock today: Price, market cap and performance in 2025 On performance, JNJ has easily outpaced
2 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock Today: High Price, High Expectations As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,057–$1,060 per share, down roughly 1–2% on the day but still close to its recent record highs.MarketBeat At this level: In short, LLY is priced as a hyper‑growth stock, not a traditional defensive pharma name. The rest of the
2 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc (LSE: GSK, NYSE: GSK) heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on whether the pipeline can deliver enough growth to meet GSK’s ambitious 2031 revenue targets. Hargreaves Lansdown+2Yahoo Finance+2 This overview pulls together the key share‑price moves, fresh news from 2 December, Street forecasts and the main bull and bear arguments around
2 December 2025
··
Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer’s share price is exploding today. On 2 December 2025, the German blue chip (ISIN DE000BAY0017, ticker BAYN) is trading around €34–35 on Xetra, up roughly 13% intraday and at a fresh year high.FinanzNachrichten.de+1 The trigger: a major twist in the U.S. Roundup™ glyphosate litigation – and a renewed wave of analyst upgrades and fresh pipeline news that could reshape the investment story. Below is a full rundown of today’s news, forecasts and analyses around Bayer stock, and what they may mean for investors. 1. Why Bayer Stock Is Surging Today U.S. government backs Bayer in Roundup case On 1 December 2025, the U.S. Solicitor General filed a brief supporting Bayer’s
2 December 2025
··
Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt Limited has suddenly jumped back into the market spotlight. On 2 December 2025, the Wockhardt share price extended a powerful breakout rally triggered by a landmark US regulatory milestone for its novel antibiotic Zaynich, making the stock one of the most-watched names in India’s pharma space this week. NDTV Profit+1 Below is a deep dive into the latest news, the Wockhardt stock’s recent performance, Zaynich’s potential, and how analysts are reading the risk–reward balance as of 2 December 2025. Wockhardt share price today: two‑day breakout on heavy volumes In Tuesday’s trade (2 December 2025), Wockhardt shares rallied for a
2 December 2025
·
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock.The Motley Fool+1 Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and how Wall Street now frames the 2026 outlook. AbbVie stock today: price, performance and valuation As of the December 1, 2025 close, AbbVie shares trade at around $225 per share, giving the company a market capitalization near $400 billion.StockAnalysis+1 Key snapshot
1 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK plc (NYSE: GSK) heads into December 2025 as one of the stronger-performing big pharma names, with the share price hovering just below a 52‑week high after a year of earnings beats, upgraded guidance, revived cancer assets and a looming CEO handover. The U.S. ADR last traded at about $47.9 (close on 28 November), with a 52‑week range of roughly $31.7–$48.7, a market cap near $95.5 billion, and a trailing P/E around 13.3.MarketBeat Several sources estimate GSK’s total return in 2025 at roughly 30–40%, far ahead of its sector, with Zacks noting a 29% year‑to‑date gain versus about 11% for
1 December 2025
··
Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November 28–30. At the close on Friday, November 28, 2025, Pfizer shares finished around $25.74, giving the drugmaker a market capitalization of roughly $146 billion.Stock Titan With U.S. equity markets shut over the weekend, that closing print is the key reference point for investors going into Monday’s session. In this pre‑open update, we break down Pfizer’s latest stock price action, key
30 November 2025
··
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. (NYSE: ABBV) heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30. As of the latest close on November 30, AbbVie shares are trading in the mid‑$220s — around $227 per share — after a strong year (roughly 30%+ total return over the past 12 months) but a softer week in which the stock slipped about 3% as traders reacted to Medicare pricing headlines and year‑end profit‑taking. TS2 Tech+1 At this level the stock offers a dividend yield a
30 November 2025
·
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Published: November 30, 2025 Eli Lilly and Company (NYSE: LLY) heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity drugs, and a late‑month pullback as investors digest aggressive US drug‑pricing deals and sky‑high valuations. With US markets closed over the weekend, there is no pre‑market quote yet for Monday, December 1. But Friday’s close, fresh analyst notes, and a burst of policy and pipeline headlines from November 28–30 set the stage for how LLY could trade when the bell
30 November 2025
·
Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are digesting in real time. As of the last trading session on Friday, November 28, 2025, Merck stock closed at $104.83, with a small after‑hours dip to $104.74.Benzinga That caps a powerful run over the past month: Merck shares have climbed roughly 22% over that period, according to new analysis from Simply Wall St.Simply Wall St Below is a deep dive
30 November 2025
·
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company (NYSE: LLY) has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as the stock market’s flagship obesity‑drug play. At the same time, fresh commentary this weekend is increasingly focused on one question: is Lilly’s stock now priced for perfection? As of the close on Friday, November 28, Eli Lilly stock traded around $1,075 per share, down roughly 2.6% on the day but still up sharply year to date and around 25–30% for
30 November 2025
·
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1 Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. Simply Wall St+1 Today’s news flow (November 29, 2025) gives investors plenty to chew on: Below is a
29 November 2025
···
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

By [Author Name] – November 29, 2025 Eli Lilly and Company’s stock has cooled after an explosive November rally that briefly turned the 149‑year‑old drugmaker into the world’s first trillion‑dollar pharmaceutical company.Reuters+1 On Friday, November 28, Eli Lilly (NYSE: LLY) closed at $1,075.47, down about 2.6% on the day, dragging the S&P 500 healthcare sector into the red even as the broader U.S. market finished higher in thin post‑holiday trading.Lilly Investor Relations+1 Despite that pullback, LLY remains up more than 30% in November and over 40% year‑to‑date, cementing its status as one of 2025’s most powerful large‑cap winners.TipRanks+1 This article
29 November 2025
·
Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Updated: November 28, 2025 Johnson & Johnson (JNJ) is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare giant a market capitalization of roughly $500 billion.FinancialContent Over the last three months, JNJ shares have climbed about 17–18%, handily beating the S&P 500’s roughly 5% gain in the same period. Year‑to‑date, the stock is up about 43%, versus around 16% for the index. Barchart notes that JNJ has been trading above both its 50‑day and 200‑day moving averages since
28 November 2025
·
Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Published: November 28, 2025 – mid‑session U.S. trading Pfizer stock price today: PFE edges higher in midday trade Pfizer stock (NYSE: PFE) is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3% from yesterday’s close near $25.72.MarketBeat That keeps PFE: Performance-wise, MarketBeat data show Pfizer is down about 3% year‑to‑date, roughly flat over the last 12 months, but up about 5% in the last month as sentiment has improved following earnings, pipeline news and an obesity‑drug acquisition.MarketBeat+1 Today’s key Pfizer stock headlines (November 28, 2025) A wave of new research and institutional‑ownership
28 November 2025
·
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc (LON:GSK; NYSE:GSK) is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs. In London, GSK’s shares are trading around 1,806p, up roughly 0.2% on the day, within a narrow intraday range of 1,802.5p–1,810p and not far from their 52‑week high of 1,830p.Investing.com+1 On the New York Stock Exchange, the company’s American Depositary Receipts (ADRs) change hands at about $48.02, virtually flat in early trading but hovering just below a 12‑month
28 November 2025
··
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin. As of 20:48 UTC on 26 November 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) traded at $48.79, up about 3.7% on the day, with intraday trading between $46.79 and $49.02 and volume near 15 million shares. On its primary listing in Copenhagen, Novo Nordisk B shares
26 November 2025
···
1 … 25 26 27 28 29 … 34

Stock Market Today

T-Mobile stock price slides into the weekend as Feb. 11 earnings update looms

T-Mobile stock price slides into the weekend as Feb. 11 earnings update looms

7 February 2026
T-Mobile US shares fell 2.2% to $197.39 Friday, underperforming peers ahead of its Feb. 11 earnings and capital markets day. The stock ended 29% below its 52-week high as investors await updated 2026–27 targets from CEO Srini Gopalan. Verizon sued T-Mobile over ad claims, which T-Mobile said it will defend. U.S. jobs and inflation data, delayed by a government shutdown, are due next week.
Go toTop